Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adriamycine · 1 trial · 1 indication
pCR is defined as no invasive cells identifiable in breast sections at surgery. Response will be measured by physical exam and breast imaging before surgery and will be evaluated according to the World Health Organization (WHO) criteria. Pathological response after surgery, will be based on the proportion of remaining tumor and post-chemotherapy changes, evaluating separately the response in the breast and in the axilla lymph nodes.
| Arm | Type | Description |
|---|---|---|
| Gemcitabine + Adriamycine + Paclitaxel | EXPERIMENTAL | Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles. |
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | - |
| Adriamycine | DRUG | - |
| Paclitaxel | DRUG | - |
Inclusion Criteria: * Stage III breast cancer disease, with histological confirmation by true-cut or open-biopsy. * Ages between 18 and 75 years old. Patients older than 70 must have an adequate quality of life to be eligible. * Patients cannot have received previous treatment with chemotherapy, ho...
Top 20 of 92 competitors
Adriamycine is used for breast cancer. It is being studied as part of a neoadjuvant treatment regimen for breast cancer patients. The drug is a small molecule oncology therapy currently in clinical development.
Adriamycine is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this drug for the treatment of breast cancer.
Adriamycine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being evaluated for its safety and efficacy in breast cancer patients.
Adriamycine has one completed clinical trial, NCT00128856, titled 'Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients'. This Phase 2 trial enrolled 46 female patients in Spain and was not randomized or double-blinded.
Adriamycine is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available information, so its exact mechanism of action is not detailed here.